Supriya Lifescience H1 revenue up 14.8% to ₹396.04 crore; Q2 profit falls
Supriya Lifescience · Pharmaceuticals & Biotechnology
Key highlights
- Q2 FY27 PAT ₹29.25 crore against ₹50.43 crore in Q2 FY26; PAT margin 14.2% against 25.2%
- Q2 FY27 revenue ₹206.30 crore, up 3.2% from ₹199.83 crore; EBITDA ₹45.40 crore with 22.0% margin
- Europe was the largest market in Q2 FY27 at 43% of revenue, up from 37% in Q2 FY26
Why it's rated major development: the year-on-year change is 42% (20% or more for adverse news)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other capex / expansion filings this fortnight
- V-MARC India Ltd announces Q2 & H1 FY27 unaudited financial results and review report
- West Coast Paper Mills approves Q2 results; ₹290 crore optical fibre capacity expansion
- JSW Energy adds 1,784 MW capacity, total installed capacity reaches 15,237 MW
- Hindalco Q2 FY27: Revenue up 39% to ₹91,708 Cr, PAT up 59% to ₹7,533 Cr
- Fujiyama Power Systems reports Q2 and H1 FY27 revenue growth and capacity expansion
- GAIL's subsidiary GMPL commissions 1.25 MTPA PTA plant at Mangalore
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.